Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • February 2021 •
  • 110 pages •
  • Report ID: 5783455 •
  • Format: PDF
The global cephalosporin market reached a value of US$ 17.46 Billion in 2020. Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.

At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market. Looking forward, the analyst expects the global cephalosporin market to exhibit moderate growth during the next five years.

Report Coverage:
Historical, Current and Future Market Trends

Market Breakup by Generation:
First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation

Market Breakup by Route of Administration:
Injection
Oral

Market Breakup by Application:
Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection
Others

Market Breakup by Region:
Asia Pacific
Europe
North America
Middle East and Africa
Latin America

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report:
How has the global cephalosporin market performed so far and how will it perform in the coming years?
What are the key regional markets in the global cephalosporin industry?
What has been the impact of COVID-19 on the global cephalosporin industry?
What is the breakup of the market based on the generation?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the global cephalosporin industry?
What are the key driving factors and challenges in the global cephalosporin industry?
What is the structure of the global cephalosporin industry and who are the key players?
What is the degree of competition in the global cephalosporin industry?
What are the profit margins in the global cephalosporin industry?